Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders

Cancer Genetics and Cytogenetics

Volumn 181, Issue 1, 2008, Pages 46-51

  Gallagher, Genevieve ^a   Horsman, Douglas E ^b   Tsang, Peter ^c   Forrest, Donna L ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; CLADRIBINE; CYCLIC GMP DEPENDENT PROTEIN KINASE; HYDROCHLOROTHIAZIDE; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; SIMVASTATIN; SPECTRIN; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 4; CHROMOSOME TRANSLOCATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DRUG DOSE INCREASE; EOSINOPHILIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTOSIS; LYMPHADENOPATHY; MALE; MAST CELL LEUKEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; MYELOPROLIFERATIVE DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 5; CYCLIC GMP-DEPENDENT PROTEIN KINASES; FEMALE; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SPECTRIN; TRANSLOCATION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 38849133643     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.10.021     Document Type: Article

References (29)

1. Tefferi A., and Gilliland G. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 19 (2006) 365-385
2. Yoon S.Y., Tefferi A., and Li C.Y. Cellular distribution of platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 104 (2000) 151-157
3. Cross N.C., and Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16 (2002) 1207-1212
4. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
5. Baxter E.J., Kulkarni S., Vizmanos J.L., Jaju R., Martinelli G., Testoni N., Hughes G., Salamanchuk Z., Calasanz M.J., Lahortiga I., Pocock C.F., Dang R., Fidler C., Wainscoat J.S., Boultwood J., and Cross N.C. Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 120 (2003) 251-256
6. Vizmanos J.L., Novo F.J., Román J.P., Baxter E.J., Lahortiga I., Larráyoz M.J., Odero M.D., Giraldo P., Calasanz M.J., and Cross N.C. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 64 (2004) 2673-2676
7. Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., Chase A.J., and Cross N.C. P53-binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(15;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 64 (2004) 7216-7219
8. Kulkarni S., Heath C., Parker S., Chase A., Iqbal S., Pocock C.F., Kaeda J., Cwynarski K., Goldman J.M., and Cross N.C. Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 60 (2000) 3592-3598
9. Pitini V., Arrigo C., Teti D., Barresi G., Righi M., and Alo G. Response to STI571 in chronic myelomonocytic leukemia with platelet-derived growth factor beta receptor involvement: a new case report. Haematologica 88 (2003) ECR18
10. Schwaller J., Anastasiadou E., Cain D., Kutok J., Wojiski S., Williams I.R., LaStarza R., Crescenzi B., Sternberg D.W., Andreasson P., Schiavo R., Siena S., Mecucci C., and Gilliland D.G. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97 (2001) 3910-3918
11. Wilkinson K., Velloso E.R., Lopes L.F., Lee C., Aster J.C., Shipp M.A., and Aguiar R.C. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102 (2003) 4187-4190
12. Ross T.S., Bernard O.A., Berger R., and Gilliland D.G. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor(PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91 (1998) 4419-4426
13. Walz C., Metzgeroth G., Haferlach C., Schmitt-Graeff A., Fabarius A., Hagen V., Prummer O., Rauh S., Hehlmann R., Hochhaus A., Cross N.C., and Reiter A. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor B gene. Haematol 92 (2007) 163-169
14. Rosati R., La Starza R., Luciano L., Gorello P., Matteucci C., Pierini V., Romoli S., Crescenzi B., Rotoli B., Martelli M.F., Pane F., and Mecucci C. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia 20 (2006) 1623-1624
15. David M., Cross N.C., Burgstaller S., Chase A., Curtis C., Dang R., Gardembas M., Goldman J.M., Grand F., Hughes G., Huguet F., Lavender L., McArthur G.A., Mahon F.X., Massimini G., Melo J., Rousselot P., Russell-Jones R.J., Seymour J.F., Smith G., Stark A., Waghorn K., Nikolova Z., and Apperley J.F. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109 (2007) 61-64
16. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., Marin D., Nikolova Z., Olavarria E., Silberman S., Schultheis B., Cross N.C., and Goldman J.M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New Engl J Med 347 (2002) 481-487
17. Pardanani A., and Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104 (2004) 1931-1939
18. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., and Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood 100 (2002) 1088-1091
19. Krystal G.W. Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res 28 Suppl. 1 (2004) S53-S59
20. Dalal B.I., Horsman D.E., Bruyere H., and Forrest D.L. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol 82 (2007) 77-79
21. Keene P., Mendelow B., Pinto M.R., Bezwoda W., MacDougall L., Falkson G., Ruff P., and Bernstein R. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. Br J Haematol 67 (1987) 25-31
22. Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., Maserati E., Pasquali F., and Panarello C. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 64 (2004) 2649-2651
23. Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., and Saito H. Fusion of the platelet-derived growth factor receptor β to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90 (1997) 4271-4277
24. Levine R.L., Wadleigh M., Sternberg D.W., Wlodarska I., Galinsky I., Stone R.M., DeAngelo D.J., Gilliland D.G., and Cools J. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 19 (2005) 27-30
25. Magnusson M.K., Meade K.E., Brown K.E., Arthur D.C., Krueger L.A., Barrett A.J., and Dunbar C.E. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemia. Blood 98 (2001) 2518-2525
26. Rosati R., La Starza R., Bardi A., Luciano L., Matteucci C., Pierini V., Romoli S., Crescenzi B., Pane F., Cuneo A., Martelli M.F., Cools J., Marynen P., and Mecucci C. PDGFRB fuses to TPM3 in the t(1;5)(q23;q33) of chronic eosinophilic leukemia and to NDE1 in the t(5;16)(q33;p13) of chronic myelomonocytic leukemia. [Abstract]. Haematologica 91 Suppl. 1 (2006) 214
27. Feil R., and Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep 7 (2006) 149-153
28. Chang J.G., Scarpa A., Eddy R.L., Byers M.G., Harris A.S., Morrow J.S., Watkins P., Shows T.B., and Forget B.G. Cloning of a portion of the chromosomal gene and cDNA for human β-fodrin, the nonerythroid form of β-spectrin. Genomics 17 (1993) 287-293
29. Bennett V., and Baines A.J. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 81 (2001) 1353-1392